Inflammation: A mechanism of depression?

Neuroscience Bulletin

Volumn 30, Issue 3, 2014, Pages 515-523

  Han, Qiu Qin ^a   Yu, Jin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

5 HT; cytokines; depression; hypothalamic pituitary adrenal axis; inflammation; neuroplasticity

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; NORADRENALIN;

BRAIN REGION; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; HIPPOCAMPUS; HUMAN; INFLAMMATION; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NONHUMAN; PREVALENCE; REVIEW; SIGNAL TRANSDUCTION; BRAIN; COMPLICATION; METABOLISM; PATHOLOGY;

BRAIN; CYTOKINES; DEPRESSION; HUMANS; INFLAMMATION;

EID: 84902383029     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-013-1439-3     Document Type: Review

References (104)

1. Compton WM, Conway KP, Stinson FS, Grant BF. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. Am J Psychiatry 2006, 163: 2141-2147. (Pubitemid 46114235)
2. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993, 29: 85-96. (Pubitemid 23334116)
3. Sharpley CF, Agnew LL. Cytokines and depression: findings, issues, and treatment implications. Rev Neurosci 2011, 22: 295-302.
4. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 2005, 29: 891-909. (Pubitemid 40755469)
5. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71: 171-186.
6. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996, 87: 2095-2147.
7. Plata-Salaman CR, Ilyin SE. Interleukin-1beta (IL-1beta)-induced modulation of the hypothalamic IL-1beta system, tumor necrosis factor-alpha, and transforming growth factor-beta1 mRNAs in obese (fa/fa) and lean (Fa/Fa) Zucker rats: implications to IL-1beta feedback systems and cytokine-cytokine interactions. J Neurosci Res 1997, 49: 541-550.
8. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000, 157: 683-694.
9. Macaluso M, Drevets WC, Preskorn SH. How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression. J Psychiatr Pract 2012, 18: 281-286.
10. Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011, 36: 2375-2394.
11. Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Bar M, et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007, 17: 774-780. (Pubitemid 47588862)
12. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007, 2007: 76396.
13. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67: 446-457.
14. Kahl KG, Bens S, Ziegler K, Rudolf S, Dibbelt L, Kordon A, et al. Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biol Psychiatry 2006, 59: 667-671. (Pubitemid 43357963)
15. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun 2007, 21: 901-912. (Pubitemid 47285684)
16. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27: 24-31. (Pubitemid 43083561)
17. Diniz BS, Teixeira AL, Talib L, Gattaz WF, Forlenza OV. Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. Am J Geriatr Psychiatry 2010, 18: 172-176.
18. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33: 722-726.
19. Himmerich H, Milenovic S, Fulda S, Plumakers B, Sheldrick AJ, Michel TM, et al. Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J Psychiatr Res 2010, 44: 1052-1057.
20. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003, 170: 429-433. (Pubitemid 38010515)
21. Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, Hosseini M, Amini H, et al. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res 2010, 178: 112-115.
22. Shelton RC, Miller AH. Inflammation in depression: is adiposity a cause? Dialogues Clin Neurosci 2011, 13: 41-53.
23. Wu XP, Wang D, Song ZJ, Sun CZ, Xiao XL, He YD, et al. [Impact of anxiety-depression symptoms on clinical recovery and serum TNF-alpha and IL-6 of patients with burns]. Sichuan Da Xue Xue Bao Yi Xue Ban 2008, 39: 105-107.
24. Jehn CF, Kuhnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, et al. Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. Integr Cancer Ther 2010, 9: 270-275.
25. Liu Y, Ho RC, Mak A. The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int J Rheum Dis 2012, 15: 183-187.
26. Cheng J, Zhang J, Lu C, Wang L. Using optogenetics to translate the "inflammatory dialogue" between heart and brain in the context of stress. Neurosci Bull 2012, 28: 435-448.
27. Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun 2007, 21: 727-735.
28. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 2012, 83: 495-502.
29. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011, 130: 226-238.
30. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9: 46-56. (Pubitemid 350295688)
31. Freidin M, Bennett MV, Kessler JA. Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta. Proc Natl Acad Sci U S A 1992, 89: 10440-10443.
32. Breder CD, Tsujimoto M, T erano Y, Scott DW, Saper CB. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J Comp Neurol 1993, 337: 543-567. (Pubitemid 23323643)
33. Bethea JR, Chung IY, Sparacio SM, Gillespie GY, Benveniste EN. Interleukin-1 beta induction of tumor necrosis factor-alpha gene expression in human astroglioma cells. J Neuroimmunol 1992, 36: 179-191.
34. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998, 43: 40-49. (Pubitemid 28069166)
35. Tweardy DJ, Mott PL, Glazer EW. Monokine modulation of human astroglial cell production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. I. Effects of IL-1 alpha and IL-beta. J Immunol 1990, 144: 2233-2241. (Pubitemid 20106565)
36. Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988, 240: 321-324.
37. Rothwell NJ, Luheshi G. Pharmacology of interleukin-1 actions in the brain. Adv Pharmacol 1994, 25: 1-20.
38. Hanisch UK, Quirion R. Interleu kin-2 as a neuroregulatory cytokine. Brain Res Brain Res Rev 1995, 21: 246-284.
39. Konishi Y, Chui DH, Kunishita T, Yamamura T, Higashi Y, Tabira T. Demonstration of interleukin-3 receptor-associated antigen in the central nervous system. J Neurosci Res 1995, 41: 572-582.
40. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 1995, 154: 450-458.
41. Benveniste EN, Sparacio SM, Norris JG, Grenett HE, Fuller GM. Induction and regulation of interleukin-6 gene expression in rat astrocytes. J Neuroimmunol 1990, 30: 201-212. (Pubitemid 20362753)
42. Ehrlich LC, Hu S, Sheng WS, Sutton RL, Rockswold GL, Peterson PK, et al. Cytokine regulation of human microglial cell IL-8 production. J Immunol 1998, 160: 1944-1948. (Pubitemid 28106484)
43. Wong ML, Bongiorno PB, Rettori V, Mc Cann SM, Licinio J. Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci U S A 1997, 94: 227-232. (Pubitemid 27027191)
44. Stalder AK, Pagenstecher A, Yu NC, Ki ncaid C, Chiang CS, Hobbs MV, et al. Lipopolysaccharide-induced IL-12 expression in the central nervous system and cultured astrocytes and microglia. J Immunol 1997, 159: 1344-1351. (Pubitemid 127484113)
45. Bethea JR, Gillespie GY, Benveniste EN. Interleukin-1 beta induction of TNF-alpha gene expression: involvement of protein kinase C. J Cell Physiol 1992, 152: 264-273.
46. Tilders FJ, DeRijk RH, Van Dam AM, Vinc ent VA, Schotanus K, Persoons JH. Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: routes and intermediate signals. Psychoneuroendocrinology 1994, 19: 209-232. (Pubitemid 24182349)
47. Monje FJ, Cabatic M, Divisch I, Kim EJ, Herkner KR, Binder BR, et al. Constant darkness induces IL-6-dependent depression-like behavior through the NF-kappaB signaling pathway. J Neurosci 2011, 31: 9075-9083.
48. Marini H, Altavilla D, Bellomo M, Adamo E B, Marini R, Laureanti F, et al. Modulation of IL-1 beta gene expression by lipid peroxidation inhibition after kainic acid-induced rat brain injury. Exp Neurol 2004, 188: 178-186. (Pubitemid 38748816)
49. Kumagai N, Chiba Y, Hosono M, Fujii M, Kaw amura N, Keino H, et al. Involvement of pro-inflammatory cytokines and microglia in an age-associated neurodegeneration model, the SAMP10 mouse. Brain Res 2007, 1185: 75-85. (Pubitemid 350166311)
50. Feuerstein GZ, Wang X, Barone FC. Inflammat ory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Ann N Y Acad Sci 1997, 825: 179-193. (Pubitemid 27503715)
51. Minami M, Kuraishi Y, Satoh M. Effects of ka inic acid on messenger RNA levels of IL-1 beta, IL-6, TNF alpha and LIF in the rat brain. Biochem Biophys Res Commun 1991, 176: 593-598.
52. Siren AL, Heldman E, Doron D, Lysko PG, Yue TL, Liu Y, et al. Release of proinflammatory and prothrombotic mediators in the brain and peripheral circulation in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Stroke 1992, 23: 1643-1650; discussion 1650-1641.
53. Alvarez XA, Franco A, Fernandez-Novoa L, Cacab elos R. Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels. Agents Actions 1994, 41 Spec No: C70-72. (Pubitemid 24199931)
54. Shohami E, Novikov M, Bass R, Yamin A, Gallily R. Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. J Cereb Blood Flow Metab 1994, 14: 615-619. (Pubitemid 24198404)
55. Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol 1993, 42: 177-185.
56. van der Werf-Eldering MJ, Riemersma-van der Lek R F, Burger H, Holthausen EA, Aleman A, Nolen WA. Can variation in hypothalamic-pituitary-adrenal (HPA)-axis activity explain the relationship between depression and cognition in bipolar patients? PLoS One 2012, 7: e37119.
57. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993, 77: 1690-1694. (Pubitemid 24000936)
58. Himmerich H, Binder EB, Kunzel HE, Schuld A, Lucae S, Uhr M, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 2006, 60: 882-888. (Pubitemid 44527894)
59. O'Keane V, Frodl T, Dinan TG. A review of Atypical depression in relation to the course of depression and changes in HPA axis organization. Psychoneuroendocrinology 2012, 37: 1589-1599.
60. Frost P, Bornstein S, Ehrhart-Bornstein M, O'Kirwan F, Hutson C, Heber D, et al. The prototypic antidepressant drug, imipramine, but not Hypericum perforatum (St. John's Wort), reduces HPA-axis function in the rat. Horm Metab Res 2003, 35: 602-606. (Pubitemid 37445328)
61. Myint AM, Kim YK. Cytokine-serotonin interaction thro ugh IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 2003, 61: 519-525. (Pubitemid 37411894)
62. Catena-Dell'Osso M, Rotella F, Dell'Osso A, Fagiolini A, Marazziti D. Inflammation, serotonin and major depression. Curr Drug Targets 2013, 14: 571-577.
63. Pemberton LA, Kerr SJ, Smythe G, Brew BJ. Quinolinic ac id production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res 1997, 17: 589-595. (Pubitemid 27451155)
64. Fujigaki S, Saito K, Sekikawa K, Tone S, Takikawa O, Fuj ii H, et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001, 31: 2313-2318. (Pubitemid 32785349)
65. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygena se (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004, 29: 11-17. (Pubitemid 38570008)
66. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115 (Pt 5): 1249-1273.
67. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002, 5: 375-388. (Pubitemid 35470357)
68. Dantzer R. Cytokine, sickness behavior, and depression. Immu nol Allergy Clin North Am 2009, 29: 247-264.
69. Sublette ME, Postolache TT. Neuroinflammation and depression: the role of indoleamine 2,3-dioxygenase (IDO) as a molecular pathway. Psychosom Med 2012, 74: 668-672.
70. Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 2011, 18: 2257-2262.
71. Lesch KP, Mossner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998, 44: 179-192. (Pubitemid 28378300)
72. Staley JK, Malison RT, Innis RB. Imaging of the serotonergic sys tem: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry 1998, 44: 534-549. (Pubitemid 28496680)
73. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30: 899-905. (Pubitemid 43795377)
74. Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998, 349: 317-324. (Pubitemid 28277103)
75. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. Enha ncement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998, 33: 251-254. (Pubitemid 28418296)
76. Abe S, Hori T, Suzuki T, Baba A, Shiraishi H, Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 1999, 24: 359-363. (Pubitemid 29072044)
77. Kugaya A, Kagaya A, Uchitomi Y, Yokota N, Yamawaki S. Effect of inter feron-alpha on DOI-induced wet-dog shakes in rats. J Neural Transm 1996, 103: 947-955. (Pubitemid 26383830)
78. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994, 643: 40-49. (Pubitemid 24115074)
79. Hurst SM, Collins SM. Mechanism underlying tumor necrosis factor-alpha suppression of norepinephrine release from rat myenteric plexus. Am J Physiol 1994, 266: G1123-1129.
80. Ando T, Dunn AJ. Mouse tumor necrosis factor-alpha increases brain trypt ophan concentrations and norepinephrine metabolism while activating the HPA axis in mice. Neuroimmunomodulation 1999, 6: 319-329. (Pubitemid 29418460)
81. Moron JA, Zakharova I, Ferrer JV, Merrill GA, Hope B, Lafer EM, et al. Mi togen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003, 23: 8480-8488. (Pubitemid 37158747)
82. Wu HQ, Rassoulpour A, Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm 2007, 114: 33-41. (Pubitemid 46018673)
83. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-al pha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997, 747: 348-351. (Pubitemid 27077413)
84. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, et al. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry 2007, 62: 1324-1333. (Pubitemid 350060899)
85. Kitagami T, Yamada K, Miura H, Hashimoto R, Nabeshima T, Ohta T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 2003, 978: 104-114. (Pubitemid 36780963)
86. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depr ession: a literature review. CNS Spectr 2008, 13: 501-510. (Pubitemid 351965454)
87. Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, et al. In terleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 2003, 23: 8692-8700. (Pubitemid 37176649)
88. Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 2000, 7: 153-159. (Pubitemid 30204821)
89. Dowben JS, Grant JS, Keltner NL. Ketamine as an alternative treatment for treatme nt-resistant depression. Perspect Psychiatr Care 2013, 49: 2-4.
90. Mathews DC, Zarate CA, Jr. Current status of ketamine and related compounds for de pression. J Clin Psychiatry 2013, 74: 516-517.
91. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treat ment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 2013, 47: 710-727.
92. Howland RH. Ketamine for the treatment of depression. J Psychosoc Nurs Ment Health Serv 2013, 51: 11-14.
93. Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: s tressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135: 659-678. (Pubitemid 41407732)
94. Fuchs E, Czeh B, Kole MH, Michaelis T, Lucassen PJ. Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol 2004, 14 Suppl 5: S481-490. (Pubitemid 39531609)
95. Carlson PJ, Singh JB, Zarate CA, Jr., Drevets WC, Manji HK. Neural circuitry and neurop lasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 2006, 3: 22-41. (Pubitemid 43279517)
96. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000, 48: 755-765.
97. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, N AG, et al. Enhancing neuronal plast icity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003, 53: 707-742. (Pubitemid 39658487)
98. Kaneko N, Kudo K, Mabuchi T, Takemoto K, Fujimaki K, Wati H, et al. Suppression of cell pr oliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006, 31: 2619-2626. (Pubitemid 44764159)
99. Alboni S, Gibellini L, Montanari C, Benatti C, Benatti S, Tascedda F, et al. N-acetyl-cyste ine prevents toxic oxidative effects induced by IFN-alpha in human neurons. Int J Neuropsychopharmacol 2013, 16: 1849-1865.
100. Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neur on number: implications for aging. J Neurosci 1985, 5: 1222-1227. (Pubitemid 15098432)
101. McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci 2001, 933: 265-277. (Pubitemid 32390122)
102. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001, 2: 24-32.
103. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 2001, 11: 272-280.
104. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plastici ty and neurodegenerative disorders. Trends Neurosci 2004, 27: 589-594. (Pubitemid 39221394)